Botulism and vaccines for its prevention

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Smith, Leonard A ^a  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Botulinum neurotoxin; Botulism; Fragment C; Pentavalent botulinum toxoid; Recombinant subunit vaccine

Indexed keywords

BACTERIAL VACCINE; BOTULINUM TOXIN; BOTULINUM VACCINE; TETANUS TOXIN; UNCLASSIFIED DRUG;

BOTULISM; HUMAN; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 77950859996     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.059     Document Type: Review

References (138)

1. Van Ermengem E. Ueber einen neuer anaeroben bacillus und seine beziehunger zum botulismus. Zeit f Hyg 1897;26:1-56.
2. Leuchs J. Beitrage sur kentniss die toxin und antitoxin des bacillus botulinus. Zeit Hyg Infektionskrankh 1910;65:55-84.
3. Lamanna C. The most poisonous poison. Science 1959;130:763-72.
4. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol 1985;4:654-5.
5. McCroskey LM, Hatheway CL, Fenicia L, Pasolini B, Aureli P. Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol 1986;1:201-2.
6. Aureli P, Fenicia L, Pasolini B, Gianfranceschi M, McCroskey LM, Hatheway CL. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis 1986;154:207-11.
7. Giménez DF, Ciccarelli AS. Another type of Clostridium botulinum. Zentralbl Bakteriol Orig 1970;215:221-4.
8. Harrell WK, Green JH, Winn JF. Preparation, evaluation, and use of C. botulinum antitoxins. In: Lewis KH, Cassel Jr K, editors. Botulism proceedings of a symposium. Cincinnati: U.S. Public Health Service; 1964. p. 165-74 [PHS Pub. No 999 FP-1].
9. Hatheway CL. Clostridium botulinum and other clostridia that produce botulinum neurotoxins. In: Hauschild AHW, Dodds KL, editors. Clostridium botulinum-ecology and control in foods. NewYork: Marcel Dekker Inc.; 1992. p. 3-10.
10. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980;44: 419-48.
11. Centers for Disease Control and Prevention. Botulism in the United States, 1899-1998. Handbook for epidemiologists, clinicians and laboratory workers. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service; 1998.
12. Middlebrook JL, Franz DR. Botulinum toxins. In: Slidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I. Warfare, weaponry, and then casualty: medical aspects of chemical and biological warfare, 33. Washington, DC: Borden Institute, Walter Reed Army Medical Center; 1997. p. 643-54.
13. Gunnison JB, Meyer KF. Susceptibility of monkeys, goats and small animals to oral administration of botulinum toxin types B, C and D. J Infect Dis 1930;46:335-40.
14. Dolman CE, Murakami L. Clostridium botulinum type F with recent observations on other types. J Infect Dis 1961;109:107-28.
15. Smart JL, Roberts TA, McCullagh KG, Lucke VM, Pearson H. An outbreak of type C botulism in captive monkeys. Vet Rec 1980;107:445-6.
16. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotypes C and E: clinical trials. In: Brin ME, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin, 42. New York, NY: Lippincott Williams &Wilkins; 2002. p. 441-50.
17. Smith LA. Bacterial protein toxins as biological weapons. In: Alouf J, Popoff M, editors. The comprehensive sourcebook of bacterial protein toxins, vol. 62. London: Academic Press; 2006. p. 1019-30.
18. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-66.
19. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93.
20. Dembek Z, Smith LA, Rusnak JM. Botulinum toxin. J Dis Med Pub Health Prep 2007;1:1-13.
21. Dolly JO, Lisk G, Foran PG, Meunier F, Mohammed N, O'Sullivan G, et al. Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Brin ME, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin, vol. 8. New York, NY: Lippincott Williams &Wilkins; 2002. p. 91-102.
22. Foran P, Mohammed N, Lisk G, Nagwaney S, Lawrence G, Johnson E, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared to the long-lasting type A: basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003;278: 1363-71.
23. Erlich P. Die werthbemessung des diphtheria heil-serum und deren theoretische grundlagen. Klin Jahrb Jena 1897;6:299-326.
24. Ramon G. Pouvior floculant et pouvoir toxique de la toxine diphterique. Compt Rend de la Soc de Biol Paris 1923;89:2-4.
25. Ramon G. Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxine diphterique rendue anatoxique (anatoxine). C R Acad Sci Paris 1923;177:1338-40.
26. Ramon G. Sur la toxine et sur l'anatoxine diphtériques: pouvoir floculant et proprieties immunisantes. Ann Inst Pasteur 1924;38:1-10.
27. von Behring EA, Ransom G. Ueber Tetanusgift und Tetanusantitoxin. Deutsch MedWoch 1898;24:181-5.
28. Lowenstein E. Ueber active Schutzimpfung bei Tetanus durch Toxoide. Ztschr f Hyg u Infektionskrankh 1909;62:491-508.
29. von Eisler M, Lowenstein E. Ueber Formalinwirkung auf Tetanustoxin und andere Bakterien-toxine. Zentr f Bakt 1 Abt Orig 1911;61:271-88.
30. Weinberg M, Goy P. Recherches sur la toxine botulinque. Compt Rend Soc Biol 1924;90:269-71.
31. Graham R, Tunnicliff EA, McCulloch EC, Thorpe Jr F. The antigenic value of formalized botulinum toxins. J Am Met Vet Assoc 1929;75:21-37.
32. Graham R, Thorpe Jr F. Antigenic value of botulinum toxoids kept one year at ice box temperature. J Immunol 1931;20:305-12.
33. Velikanov IM. Experimental vaccination against botulism. Z Immunitatsforsch 1931;70:186-94.
34. Legroux R, Jeramec C. Etudes sur la toxine et l'antitoxine botuliques. Compt Rend Soc Biol 1935;120:641-3.
35. Jakobkiewicz J. Toxine et anatoxine botulique. Compt Rend Soc Biol 1936;123:262-4.
36. Jeramec C. Toxine et anatoxine botulique. Rev Immunol 1936;2:209-20.
37. Melnik MI, Starobinetz GM. Active immunization against botulism. Ann Inst Metch 1936;4:33-42.
38. Velikanov I. Experimental immunization of man against botulism. Klin Med 1934;12:1802-6.
39. Velikanov I. Immunization experimentale de l'homme contra la botulisme. Giorn Batteriol E Immunol 1936;17:451-6.
40. Nigg C, Hottle CA, Coriell LL, Rosenwald AS, Beveridge GW. Studies on botulinum toxoid, types A and B. I. Production of alum-precipitated toxoids. J Immunol 1947;55:245-54.
41. Hottle GA, Nigg C, Lichty JA. Studies on botulinum toxoids, types A and B. II. Methods for determining antigenicity in animals. J Immunol1947;55:255-62.
42. Rice CR, Pallister EF, Smith LC, Reed GB. Clostridium botulinum type A toxoids. Can J Res 1947;25:167-74.
43. Rice CE, Smith LC, Pallister EF, Reed GB. Clostridium botulinum type B toxoids. Can J Res 1947;25:175-80.
44. Rice CE. Preliminary study of antigenic activity of mixtures of Clostridium botulinum toxoid types A and B. Can J Res 1947;25:181-7.
45. Reames HR, Kakull PJ, Housewright RD, Wilson JB. Studies on botulinum toxoid, types A and B. III. Immunization of man. J Immunol 1947;55:309-24.
46. Duff JT, Wright GG, Klerer J, Moore DE, Bibler RH. Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin. J Bacteriol 1957;73:42-7.
47. Duff JT, Klerer J, Bibler RH, Moore DE, Gottfried C, Wright GG. Studies on immunity to toxins of Clostridium botulinum. II. A simplified procedure for isolation of type A toxin. J Bacteriol 1957;73:597-601.
48. Wright GG, Duff JT, Fiock MA, Devlin HB, Soderstrom RL. Studies on immunity to toxins of Clostridium botulinum. V. Detoxification of purified type A and B toxins, and the antigenicity of univalent and bivalent aluminum phosphate adsorbed toxoids. J Immunol 1960;84:384-9.
49. Fiock MA, Devine LF, Gearinger NF, Duff JT, Wright GG, Kadull PJ. Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid. J Immunol 1962;88: 277-83.
50. Cardella MA. Botulinal toxoid. In: Lewis KH, Cassel Jr K, editors. Botulism. Proc. of symposium. Cincinnati, Ohio: PHS; 1964. p. 113-30 [Publ. No. 999-EP-1].
51. Holt LB. Developments in diphtheria prophylaxis. London: William Heinemann Medical Books, Ltd.; 1950.
52. Smith LDS. Botulinum toxoids. In: Balows A, editor. Botulism: the organism, its toxin, the disease. Springfield, Illinois: Charles C Thomas Publisher; 1977. p. 152-6.
53. Fiock MA, Cardella MA, Gearinger NF. Studies on immunity to toxins of Clostridium botulinum. IX. Immunologic response of man to purified ABCDE botulinum toxoid. J Immunol 1963;90:667-702.
54. Ellis RJ. Immunobiologic agents and drugs available from the Centers for Disease Control: description, recommendations, adverse events, and serologic response. 3rd ed. Atlanta: Centers for Disease Control; 1982. p. 1.
55. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, the present, and future. Crit Rev Immunol 2007;27:303-18.
56. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin in press; December 2009:5, Issue.
57. Torii Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, et al. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 2002;20:2556-61.
58. Tong X, Ford P, Johnson V, Ionin B, Brazer S, Tranter H, et al. Bivalent AB botulinum toxoid (BBT). In: 43rd Interagency Botulism Research Coordinating Committee meeting. 2006 [Abstract].
59. Agostini H, Shone C, Ford P, Tranter H, Tong X, Johnson V. Immunogenicity and animal efficacy studies of botulinum toxoid vaccines. In: Meeting of the Interagency Botulism Research Coordinating Committee. 2008.
60. Jones RGA, Liu Y, Rigsby P, Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods 2008;337:42-8.
61. Keller JE. Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vaccine Immunol 2008;15:1374-9.
62. Helting T, Zwisler O. Enzymatic breakdown of tetanus toxin. Biochim Biophys Res Commun 1974;57:1263-70.
63. Helting TB, Zwisler O. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. J Biol Chem 1977;252:187-93.
64. Helting TB, Ronneberger HJ, Vollerthun R, Neubauer V. Toxicity of papaindigested tetanus toxin. Pathological effect of fragment B in the absence of spastic paralysis. J Biol Chem 1978;253:125-9.
65. Helting TB, Nau HH. Analysis of the immune response to papain digestion products of tetanus toxin. Acta Pathol Microbiol Scand C 1984;92:59-63.
66. Fairweather NF, Lyness VA. The complete nucleotide sequence of tetanus toxin. Nucleic Acids Res 1986;14:7809-12.
67. Fairweather NF, Lyness VA, Pickard DJ, Allen G, Thomson RO. Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol 1986;165:21-7.
68. Eisell U, Jarauschl W, Goretzki K, Henschen A, Engels J, Weller U, et al. Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J 1986;5:2495-502.
69. Fairweather NF, Lyness VA, Maskell DJ. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun 1987;55:2541-5.
70. Makoff AJ, Ballantine SP, Smallwood AE, Fairweather NF. Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Biotechnology 1989;7:1043-6.
71. Makoff AJ, Oxer MD, Romanos MA, Fairweather NF, Ballantine S. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res 1989;17:10191-202.
72. Romanos MA, Makoff AJ, Fairweather NF, Beesley KM, Slater DE, Rayment FB, et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res 1991;19:1461-7.
73. Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: a review. Yeast 1992;8:423-88.
74. Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology 1991;9:455-60.
75. Thompson DE, Brehm JK, Oultram JD, Swinfield TJ, Shone CC, Atkinson T, et al. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem 1990;189:73-81.
76. Binz T, Kurazono H, Popoff MR, Edlund MW, Sakaguchi G, Kosaki S, et al. Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D. Nucleic Acids Res 1990;18:5556.
77. Hauser D, Eklund MW, Kurazono H, Binz T, Niemann H, Gill DM, et al. Nucleotide sequence of Clostridium botulinum C1 neurotoxin. Nucleic Acids Res 1990;18:4924.
78. Kimura K, Fujii N, Tsuzuki K, Murakami T, Indoh T, Yokosawa N, et al. The complete nucleotide sequence of the gene coding for botulinum type C1 toxin in the C-ST phage genome. Biochem Biophys Res Commun 1990;171: 1304-11.
79. Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP. Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol 1992;58:2345-54.
80. Whelan SM, Elmore MJ, Bodsworth NJ, Atkinson T, Minton NP. The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin derived by nucleotide-sequence analysis of the encoding gene. Eur J Biochem 1992;204:657-67.
81. East AK, Richardson PT, Allaway D, Collins MD, Roberts TA, Thompson DE. Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Microbiol Lett 1992;96:225-30.
82. Poulet S, Hauser D, Quanz M, Niemann H, Popoff MR. Sequences of the botulinal neurotoxin E derived from Clostridium botulinum type E (strain Beluga) and Clostridium butyricum (strains ATCC 43181 and ATCC 43755). Biochem Biophys Res Commun 1992;183:107-13.
83. Campbell K, Collins MD, East AK. Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins. Biochim Biophys Acta 1993;1216:487-91.
84. Elmore MJ, Hutson RA, Collins MD, Bodsworth NJ, Whelan SM, Minton NP. Nucleotide sequence of the gene coding for proteolytic (group I) Clostridium botulinum type F neurotoxin: genealogical comparison with other clostridial neurotoxins. Syst Appl Microbiol 1995;18:23-31.
85. Thompson DE, Hutson RA, East AK, Allaway D, Collins MD, Richardson PT. Nucleotide sequence of the gene coding for Clostridium barati type F neurotoxin: comparison with other clostridial neurotoxins. FEMS Microbiol Lett 1993;108:175-82.
86. Willems A, East AK, Lawson PA, Collins MD. Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins (1993). Res Microbiol 1993;144:547-56.
87. Hutson RA, Collins MD, East AK, Thompson DE. Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr Microbiol 1994;28: 101-10.
88. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998;5:898-902.
89. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000;7:693-9.
90. Hasegawa K, Watanabe T, Suzuki T, Yamano A, Oikawa T, Sato Y, et al. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J Biol Chem 2007;24:24777-83.
91. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 2009;386:233-45.
92. Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin type F. Nat Struct Mol Biol 2009;16:789-95.
93. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995;63:2738-42.
94. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998;36:1539-48.
95. Baldwin MR, TeppWH, Pier CL, Bradshaw M, HoM, Wilson BA, et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005;73:6998-7005.
96. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008;76:1314-8.
97. Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S, et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009;27:2816-22.
98. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000;82:955-66.
99. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the recombinant vaccine candidate botulinum neurotoxin type A binding domain from Pichia pastoris. Infect Immun 1998;66:4817-22.
100. Potter KA, Zhang W, Smith LA, Meagher MM. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif 2000;19:393-402.
101. Zhang W, Smith LA, Plantz BA, Schlegel VL, Meagher MM. Design of methanol feed control in Pichia pastoris fermentations based upon a growth model. Biotechnol Prog 2002;6:1392-9.
102. Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ. Roads from vaccines to therapies. Mov Disord 2004;19:S48-52.
103. Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith TJ, Smith LA, et al. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotropic yeast Pichia pastoris. Protein Expr Purif 1998;13:1357-65.
104. Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (Hc)) immune response and protection in the rhesus monkey. Toxicon 2006;47:877-84.
105. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C andDneurotoxins. Vaccine 2007;25:4273-82.
106. Loveless BM. Clostridium botulinum neurotoxin type E binding domain from Pichia pastoris as a recombinant vaccine candidate. Master of Science Thesis. Frederick, MD: Hood College; 2001.
107. Dux MP, Barent R, Sinha J, Gouthro M, Swanson T, Barthuli A, et al. Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris. Protein Expr Purif 2006;45:359-67.
108. Byrne MP, Titball RW, Holley J, Smith LA. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin serotype F from Pichia pastoris. Protein Expr Purif 2000;18:327-37.
109. Johnson SK, Zhang W, Smith LA, Hywood-Potter KJ, Swanson ST, Schlegel VL, et al. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr Purif 2003;32:1-9.
110. Morefield GL, Chapman J, Tammariello RF, Purcell BK, Worsham PL, Smith LA, et al. Protection from multiple bacterial and toxin-mediated diseases using an intradermal vaccine array. J Immune Based Ther Vacc 2008;6:1-11.
111. Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000;18:1855-62.
112. Shyu RH, Shalo MF, Tang SS, Shyu HF, Lee CF, Tsai MH, et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 2000;7:51-7.
113. Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003;21:3110-7.
114. Jathoul AP, Holley JL, Garmory HS. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004;22:3942-6.
115. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001;69:5709-15.
116. Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006;24: 6886-92.
117. Yu YZ, Zhang SM, Sun ZW, Wang S, Yu WY. Enhanced immune responses using plasmid DNA replicon encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007;25:8843-50.
118. Zeng M, Xu Q, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirusvectored vaccine. Vaccine 2007;27:7540-8.
119. Xu QF, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal is effective in protection against botulism. Gene Ther 2009;16:367-75.
120. Foynes S, Holley JL, Garmony HS, Titball RW, Fairweather NF. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F Hc fragment. Vaccine 2003;21:1052-9.
121. Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 2003;71:1147-54.
122. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007;75:3043-54.
123. Smith LA, Rusnak JM. Botulism vaccines and the immune response. In: Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Botulinum toxin: therapeutic clinical practice & science. Philadelphia: Saunders Elsevier; 2009. p. 374-88.
124. Smith LA, Henderson I. Vaccines to protect against neurotoxins. In: Foster KA, Hambleton P, Shone CC, editors. Treatment from toxins. The therapeutic potential of Clostridial neurotoxins. Boca Raton, FL: Taylor & Francis Group, CRC Press; 2006. p. 75-106.
125. Mckee Jr KT, Greenberg RN, Swiderski W, Plummer EA, Starner RA, Henderson I. Initial evaluation of a recombinant Clostridium botulinum A/B vaccine (rBV A/B) in healthy volunteers. In: Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2005. p. G-918.
126. Cooper MS. Antitoxins to C. botulinum. In: Lewis KH, Cassel Jr K, editors. Botulism proceedings of a symposium. Cincinnati: U.S. Public Health Service; 1964. p. 147-64 [PHS Pub. No 999 FP-1].
127. Henderson I, Shearer J, Swiderski W, Metcalfe K, Clagett M, Niemuth N, et al. Protection against botulinum neurotoxin exposure in guinea pigs passively immunized with immune globulin purified from human volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). In: Presented at the ninth annual conference on vaccine research. 2006. p. S19.
128. Swiderski W, Greenberg RN, Hoover DL, McKee KT, Starner RA, Henderson I. Impact of adjuvant and immunogenicity of a recombinant botulinum vaccine A/B in healthy adult volunteers. In: Presented at the 42nd Annual Interagency Botulinum Research Coordinating Committee Meeting (IBRCC). 2005. p. P26.
129. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manuch M, Gibert M, et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004;572:299-306.
130. Kiyatkin N, Maksymowych AB, Simpson LL. Induction of an immune response by an oral administration of recombinant botulinum toxin. Infect Immun 1997;65:4586-91.
131. Jensen MJ, Smith TJ, AhmedSA, Smith LA. Expression, purification, and efficacy of type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 2003;41:691-701.
132. Gilsdorf J, Gul N, Smith LA. Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr Purif 2006;46:256-67.
133. Webb RP, Smith TJ, Wright P, Brown J, Smith LA. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 2009;27:4490-7.
134. Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, Nasser Z, et al. Localization of the sites and characterization of the mechanism by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 2009;27:2616-24.
135. Smith LA, Byrne M. Vaccines for preventing botulism. In: Brin M, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams &Wilkens; 2002. p. 427-40.
136. Chaddock JA, Herbert MH, Ling RJ, Alexander FCG, Fooks SJ, Revell DF, et al. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr Purif 2002;25:219-28.
137. Shone C, Agostini H, Clancy J, Gu M, Yang HH, Chu Y, et al. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun 2009;77:2795-801.
138. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR. Recombinant holotoxoid vaccine against botulism. Infect Immun 2008;76:437-42.